Cargando…

The renoprotective effect of esaxerenone independent of blood pressure lowering: a post hoc mediation analysis of the ESAX-DN trial

Angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs) are recommended as first-line drugs for hypertension with diabetic nephropathy owing to their renoprotective effect; however, their effect beyond lowering blood pressure (BP) has not been confirmed. Recent stud...

Descripción completa

Detalles Bibliográficos
Autores principales:	Okuda, Yasuyuki, Ito, Sadayoshi, Kashihara, Naoki, Shikata, Kenichi, Nangaku, Masaomi, Wada, Takashi, Sawanobori, Tomoko, Taguri, Masataka
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Nature Singapore 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9899688/ https://www.ncbi.nlm.nih.gov/pubmed/36100672 http://dx.doi.org/10.1038/s41440-022-01008-w

Ejemplares similares

Efficacy and safety of esaxerenone (CS-3150) in Japanese patients with type 2 diabetes and macroalbuminuria: a multicenter, single-arm, open-label phase III study
por: Ito, Sadayoshi, et al.
Publicado: (2021)

Reduction in the magnitude of serum potassium elevation in combination therapy with esaxerenone (CS‐3150) and sodium–glucose cotransporter 2 inhibitor in patients with diabetic kidney disease: Subanalysis of two phase III studies
por: Shikata, Kenichi, et al.
Publicado: (2022)

Effect of the Nonsteroidal Mineralocorticoid Receptor Blocker, Esaxerenone, on Nocturnal Hypertension: A Post Hoc Analysis of the ESAX-HTN Study
por: Kario, Kazuomi, et al.
Publicado: (2020)

Antihypertensive effects and safety of esaxerenone in patients with moderate kidney dysfunction
por: Ito, Sadayoshi, et al.
Publicado: (2020)

Renoprotective Effect of the Mineralocorticoid Receptor Antagonist Esaxerenone
por: Oshima, Akira, et al.
Publicado: (2021)

Factors Associated with the Antihypertensive Effect of Esaxerenone and Serum Potassium Elevation: A Pooled Analysis of Seven Phase III Studies
por: Ito, Sadayoshi, et al.
Publicado: (2023)

Effect of esaxerenone on nocturnal blood pressure and natriuretic peptide in different dipping phenotypes
por: Kario, Kazuomi, et al.
Publicado: (2021)

Long-term phase 3 study of esaxerenone as mono or combination therapy with other antihypertensive drugs in patients with essential hypertension
por: Rakugi, Hiromi, et al.
Publicado: (2019)

Efficacy and safety of esaxerenone (CS-3150) for the treatment of essential hypertension: a phase 2 randomized, placebo-controlled, double-blind study
por: Ito, Sadayoshi, et al.
Publicado: (2019)

Efficacy and safety of dosage-escalation of low-dosage esaxerenone added to a RAS inhibitor in hypertensive patients with type 2 diabetes and albuminuria: a single-arm, open-label study
por: Itoh, Hiroshi, et al.
Publicado: (2019)

Efficacy and safety of esaxerenone (CS-3150), a newly available nonsteroidal mineralocorticoid receptor blocker, in hypertensive patients with primary aldosteronism
por: Satoh, Fumitoshi, et al.
Publicado: (2020)

Effects of Repeated Oral Administration of Esaxerenone on the Pharmacokinetics of Midazolam in Healthy Japanese Males
por: Toyama, Kaoru, et al.
Publicado: (2021)

Importance of glomerular filtration rate change as surrogate endpoint for the future incidence of end-stage renal disease in general Japanese population: community-based cohort study
por: Kanda, Eiichiro, et al.
Publicado: (2017)

Observation period for changes in proteinuria and risk prediction of end‐stage renal disease in general population
por: Usui, Tomoko, et al.
Publicado: (2018)

Renoprotective effects of incretin‐based drugs: A novel pleiotropic effect of dipeptidyl peptidase‐4 inhibitor
por: Kodera, Ryo, et al.
Publicado: (2015)

New measures against chronic kidney diseases in Japan since 2018
por: Fukui, Akira, et al.
Publicado: (2019)

Pharmacokinetic interactions of esaxerenone with amlodipine and digoxin in healthy Japanese subjects
por: Kirigaya, Yoshiaki, et al.
Publicado: (2020)

eGFR slope as a surrogate endpoint for clinical study in early stage of chronic kidney disease: from The Japan Chronic Kidney Disease Database
por: Itano, Seiji, et al.
Publicado: (2023)

Feasibility of fluorescence energy transfer system for imaging the renoprotective effects of aliskiren in diabetic mice
por: Kidokoro, Kengo, et al.
Publicado: (2016)

Summary of the 2018 ISN Frontiers Meeting: Kidney Disease and Cardiovascular Disease
por: Kume, Shinji, et al.
Publicado: (2018)

Antihypertensive Effects of Esaxerenone in Older Patients with Primary Aldosteronism
por: Fujimoto, Masanori, et al.
Publicado: (2023)

Pharmacokinetics and Safety of Single-Dose Esaxerenone in Japanese Subjects with Mild to Moderate Hepatic Impairment
por: Kurata, Akifumi, et al.
Publicado: (2019)

A Patient with Bilateral Primary Aldosteronism Refractory to Oral Eplerenone Who Responded to Esaxerenone with Increased Renin Activity
por: Okamura, Keisuke, et al.
Publicado: (2020)

A circulating permeability factor in focal segmental glomerulosclerosis: the hunt continues
por: Wada, Takehiko, et al.
Publicado: (2015)

Data Delivery Method Based on Neighbor Nodes' Information in a Mobile Ad Hoc Network
por: Kashihara, Shigeru, et al.
Publicado: (2014)

Introducci©đn a la Uni©đn Europea : un an©Łlisis desde la econom©Ưa /
por: Munõz de Bustillo Llorente, Rafael
Publicado: (1997)

Body Weight Control by a High-Carbohydrate/Low-Fat Diet Slows the Progression of Diabetic Kidney Damage in an Obese, Hypertensive, Type 2 Diabetic Rat Model
por: Ohtomo, Shuichi, et al.
Publicado: (2010)

Introducci©đn a la Filosof©Ưa de la Educaci©đn
por: OĆonnor, D.J
Publicado: (1971)

ODP190 Efficacy of Esaxerenone on Hypertensive Patients with Type 2 Diabetes or Those with Impaired Glucose Tolerance
por: Kuwabara, Saki, et al.
Publicado: (2022)

Effects of itraconazole and rifampicin on the single‐dose pharmacokinetics of the nonsteroidal mineralocorticoid receptor blocker esaxerenone in healthy Japanese subjects
por: Kirigaya, Yoshiaki, et al.
Publicado: (2020)

Management of hyperkalemia during treatment with mineralocorticoid receptor blockers: findings from esaxerenone
por: Rakugi, Hiromi, et al.
Publicado: (2020)

Lymphoid EVA1 Expression Is Required for DN1-DN3 Thymocytes Transition
por: Iacovelli, Stefano, et al.
Publicado: (2009)

Efficacy and Safety of Esaxerenone in Hypertensive Patients with Diabetic Kidney Disease: A Multicenter, Open-Label, Prospective Study
por: Uchida, Haruhito A., et al.
Publicado: (2022)

A Selective Mineralocorticoid Receptor Blocker, Esaxerenone, Attenuates Vascular Dysfunction in Diabetic C57BL/6 Mice
por: Munkhjargal, Uugantsetseg, et al.
Publicado: (2023)

Introducci©đn al electromagnetismo /
por: Popović, Zoya B.
Publicado: (2001)

Pabell©đn de cancerosos /
por: Solzhenitsyn, Aleksandr Isaevich, 1918-2008
Publicado: (1969)

Jap©đn se hunde /
por: Komatsu, Sakyō
Publicado: (1978)

The role of oxidative stress and hypoxia in renal disease
por: Honda, Tomoko, et al.
Publicado: (2019)

Antecedentes hist©đricos de la formaci©đn de la naci©đn cubana /
por: Opatrný, Josef
Publicado: (1986)

Implication of Mineralocorticoid Receptor Antagonist Esaxerenone in Patients With Heart Failure With Preserved Ejection Fraction
por: Imamura, Teruhiko, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jp4d8qrao3nbqfmr4c2h2gtbjm